Today, a Director at Meridian Bioscience Inc (NASDAQ: VIVO), McIlwraith John, bought shares of VIVO for $31.24K.
Following this transaction McIlwraith John’s holding in the company was increased by 50% to a total of $92.7K. Following McIlwraith John’s last VIVO Buy transaction on February 26, 2018, the stock climbed by 1.4%.
See today’s analyst top recommended stocks >>
Based on Meridian Bioscience Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $51.74 million and quarterly net profit of $6.83 million. In comparison, last year the company earned revenue of $50.14 million and had a net profit of $240K. VIVO’s market cap is $654.4M and the company has a P/E ratio of 27.59. Currently, Meridian Bioscience Inc has an average volume of 30.49K.
Five different firms, including Canaccord Genuity and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, purified reagents, and related products. It also offers biopharmaceutical enabling technologies. It operates through the Diagnostics and Life Science segments.
